tions during high-risk pregnancy (20). To con-tribute to the limited body of literature, we eval-uated the safety and efficacy of enoxaparin in pregnant patients requiring prophylactic antico-agulation during pregnancy, and developed a protocol for the use and monitoring of enoxa-parin in this population. Information regardin Anesthesia has institutional guidelines regarding management of antithrombotic therapy for neuraxial procedures. While low molecular weight heparins (LMWH), such as enoxaparin and dalteparin, and unfractionated heparin (UFH) are safe in pregnancy and do not cross the placenta8, the risk of deliver . Enoxaparin has been increasingly used over th e past 20 years in pregnant wome n at risk of thrombosis and pregnancy complications. The main in dications are prophylaxis of venou Warfarin should be avoided during pregnancy. It crosses the placenta and increases the risk of miscarriage, stillbirth, embryopathy (nasal hypoplasia or stippled epiphyses), central nervous system.. Pregnancy and the Puerperium This is the third edition of this guideline, first published in 2004 under the title 'Thromboprophylaxis during Pregnancy, Labour and after Vaginal Delivery' and revised in 2009 under the title 'Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium'. Executive summary of.
. The jury is out about the optimal dose, though Pregnancy is well-known hypercoagulable state and inherited thrombophilias can further increase the risk for maternal venous thromboembolism (VTE). The ACOG recommendations (July 2018) address the different thrombophilias as well as associations with possible adverse pregnancy outcomes Continue oral anticoagulation (warfarin/DOAC) with frequent pregnancy testing OR Transition to LMWH (preferred to UFH) Initial dosing is the same as MHV: Twice daily dosing is still preferred during pregnancy due to enhanced renal clearanc
Anticoagulation During Pregnancy: Evolving Strategies With a Focus on Mechanical Valves. J Am Coll Cardiol 2016;68:1804-1813. The following are nine key points to remember from this review article on the use of anticoagulant medications during pregnancy: Pregnancy is a known hypercoagulable state. For example, there is a five-fold increased. Peak antiXa level. q2 weeks (check 4 hrs after dose) Goal: 0.5-1 units/ml (for q12h dosing of LMWH) Adjust LMWH dosing if needed, according to suggestions below. LMWH dosage adjustments based on peak antiXa levels. [from Monagle P et al. Chest 2001; 119 (suppl 1): 344-370] Peak antiXa level (units/ml) Hold next dose. Dosage change
Formation of blood clots, or venous thromboemboli (VTE) in pregnancy can have dangerous and even life-threatening effects on the mother and fetus. Enoxaparin is the preferred medicine to prevent clotting in pregnant patients who are at risk for VTE, because it has been studied to be safe and effective in pregnancy without any harms to the fetus Neither unfractionated heparin nor enoxaparin crosses the placenta, and both are considered safe to use in pregnancy. 58-60 As such, during an admission for trauma, pregnant patients should receive 30 mg of enoxaparin twice daily titrated by anti-Xa levels targeting a peak range of 0.2 to 0.4 IU/mL or a trough range of 0.1 to 0.2 IU/mL Use of low dose of aspirin and low molecular weight heparin (Enoxaparin) is safe in pregnancy and it improves foetal outcome (13). Bleeding is a potential complication of anticoagulant therapy, heparin induced thrombocytopenia has been observed less commonly in patients treated with LMWH Therapeutic regimen during pregnancy Lovenox 1.0 mg/kg subcutaneous q 12 hours. Achieve anti factor Xa serum level of 0.5 to 1.2 u/ml four hours post injection. Dalteparin 100u/kg subcutaneous q 12 hours Enoxaparin 40 mg $5.60 $11.2 --- Enoxaparin 30 mg $4.20 $8.40 --- Fondaparinux 2.5 mg $10.81 --- --- Definitions: For the purposes of this guideline the following have been defined: 1. Extreme obesity - 2patients with a BMI > 40 kg/M 2. Renal dysfunction - patients with a CrCl< 30 mL/min or evidence of stage 4 [eGFR 15
e692S VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy 4.0.2. For lactating women using LMWH, dana-paroid, or r-hirudin who wish to breast-feed, we recommend continuing the use of LMWH, danaparoid, or r-hirudin (Grade 1B) Clinical guideline Enoxaparin - prescribing, administration and monitoring Enoxaparin is the low molecular weight heparin (LMWH) used at WUTH. This guideline covers the following: 1. Indications 2. Contraindications 3. Initiation and dose 4. Duration 5. Administration 6. Monitoring 7. Reversal 8. Discharge 9. Other guidelines 10 International guidelines support the use of low molecular weight heparins for the treatment of thromboembolism and thromboprophylaxis during pregnancy. However, evidence of the benefit and harm associated with specific low molecular weight heparins such as enoxaparin is dated. No current systematic review and meta-analysis describing the safety and efficacy of enoxaparin for thromboembolism. Shared Care Guideline for Enoxaparin (GP Summary) with agreement of the GP and when sufficient information has been received. If the GP does not agree to share care they will inform the Consultant responsible for the patient's care. This decision should be reviewed for each subsequent pregnancy. Basingstoke, Southampton & Winchester Distric Some guidelines note that intermediate dose anticoagulation can be considered for critically ill patients. 21,23,26,28 Given the variation in VTE incidence and the unknown risk of bleeding in critically ill patients with COVID-19, the COVID-19 Treatment Guidelines Panel and guideline panels of the American Society of Hematology and the American.
For prophylaxis of VTE in pregnancy, enoxaparin or tinzaparin is used. Before initiating prophylactic therapy, seek specialist advice to discuss doses and monitoring during pregnancy. Prevention of VTE in pregnancy. Assessment of risk factors for VTE is usually made at booking, throughout pregnancy and in the postnatal period lovenox - UpToDate. Showing results for Lovenox (Enoxaparin) Search instead: Low molecular weight heparin. Anticoagulant therapy in non-ST elevation acute coronary syndromes. View in Chinese. prefer fondaparinux to enoxaparin. In patients managed conservatively, enoxaparin leads to fewer adverse cardiovascular events when compared with UFH Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J. 2000 Aug. 21(16):1301-36. . Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy Initially 30 mg, followed by (by subcutaneous injection) 1 mg/kg for 1 dose, then (by subcutaneous injection) 1 mg/kg every 12 hours (max. per dose 100 mg) for up to 8 days, maximum dose applies for the first two subcutaneous doses only, then (by intravenous injection) 300 micrograms/kg for 1 dose, dose to be given at the time of procedure if the last subcutaneous dose was given more than 8 hours previously Venous-Thromboembolism-in-Pregnancy_2019-06-26.docx Page 2 of 12 1. Purpose of guideline This guideline establishes the expected measures to prevent venous thromboembolism (VTE) during pregnancy within Auckland District Health Board (Auckland DHB). Venous thromboembolism in pregnancy and in postpartum remains one of the most commo
She was prescribed 40 mg enoxaparin daily for a history of recurrent VTE; the first occurred 2 weeks postpartum in an earlier pregnancy and the second event was unprovoked. The enoxaparin dose was increased to 80 mg daily for 6 weeks until symptoms resolved and then reduced to 40 mg daily Enoxaparin, 1.5 mg per kg daily, is not approved for outpatient management of acute deep venous thrombosis or for managementof acute deep venous thrombosis in pregnant patients. Information from Objective: To review the literature on both thromboprophylaxis and treatment of venous thromboembolism (VTE) with enoxaparin in low- and high-body-weight patients and to make dosing and monitoring recommendations in these patient populations. Data sources: A search using PubMed was conducted (1995 to January 2018) using the following key words: enoxaparin, body weight, AND thromboprophylaxis.
I'm 5 weeks and 4 days and I'll be starting lovenox again in a week. blood clots are a large risk in pregnancy & you could develop them especially if you experience bleeding so im sure its a better safe than sorry approach :) Violation Reported. Report as Inappropriate. h. hadassahx3 Anticoagulation Dosing Guideline for Adult COVID-19 Patients Enoxaparin is the preferred first line anticoagulant for patients diagnosed with COVID-19. The incidence of HIT with enoxaparin is less than 1%. VTE Prophylaxis: VTE prophylaxis will be considered for COVID-19 patients who are low risk. Low risk COVID-19 patient 1 Strong recommendations included provision of pharmacological VTE prophylaxis in acutely or critically ill inpatients at acceptable bleeding risk, use of mechanical prophylaxis when bleeding risk is unacceptable, against the use of direct oral anticoagulants during hospitalization, and against extending pharmacological prophylaxis after hospital discharge
.g. appendicectomy, postpartum sterilisation 3 Hyperemesis 3 OHSS (first trimester only) 4 Current systemic infection 1 Immobility, dehydration 1 TOTA Despite limited evidence is available in this field, the guidelines issued by the American College of Chest Physicians (ACCP) suggest the use of increased doses of LMWH perioperatively for bariatric patients. 9 AFXa monitoring and dose adjustment are recommended in patients with high-risk trauma and burns, who may be at risk of subtherapeutic thromboprophylaxis. 8,44,45 This approach has been. VTE prophylaxis in pregnancy and the puerperium March 2020 MN20.9-V7-R25 The document supplement is integral to and should be read in conjunction with this guideline. Full version history is supplied in the document supplement. Full review MN20.9-V6-R25 Queensland Clinical Guidelines
ABSTRACT: Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia. The American College of Obstetricians and Gynecologists issued the Hypertension in Pregnancy Task Force Report recommending daily low-dose aspirin beginning in the late first trimester for women with a history of early-onset preeclampsia and preterm delivery at less than 34 0. The guidelines for antithrombotic therapy in adults and children were developed by an • Lovenox 1 mg/kg (maximum dose 150 mg) pregnancy, acute burns, and recurrent thrombosis despite drug treatment. Dosing adjustments and anti-Xa monitoring may be required in these patients, therefore, consider consulting Anticoagulation Service.
For pregnant women who require prophylaxis, the ASH guideline panel sug-gests against intermediate-dose prophylaxis over standard-dose prophylax-is during the antepartum period . For women who require prophylaxis during the postpartum period, the ASH guideline panel suggests either standard- or intermediate-dose LMWH prophylaxis • Identify the available treatment guidelines for the use of enoxaparin; and • Summarize the adverse reactions and risks of enoxaparin. Enoxaparin. Enoxaparin is a low molecular weight heparin (LMWH) used primarily to prevent and treat blood clots, such as deep vein thrombosis (DVT) and pulmonary embolism (PE) Conclusions. Use of low dose aspirin and enoxaparin 40 mg subcutaneously daily in patients with RPL due to antiphospholipid syndrome resulted in higher live birth rates compared to low dose aspirin alone.Solid conclusions from this study are limited due to the small number of patients, non-randomization of groups and discrepancy in number between groups because the choice of the interventional. Table 2b. Doses of enoxaparin for the initial treatment of DVT/PE if CrCl <30ml/min Weight rounded to nearest 10kg and 0.1ml VTE treatment in pregnancy For prophylaxis and treatment of VTE in pregnancy - please refer to Wirral Women and Children's Guideline no 33: Venous Thromboembolism Prophylaxis and Treatment
Enoxaparin is a type of low molecular weight heparin (LMWH), or anticoagulant, used to prevent and treat blood clots. Formation of blood clots, or venous thromboemboli (VTE) in pregnancy can have dangerous and even life-threatening effects on the mother and fetus. Enoxaparin is the preferred medicine to prevent clotting in pregnant patients who. Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management This is the third edition of this guideline. The first edition was published in April 2001 under the same title (numbered Green-top Guideline No. 28) and the second edition was published in February 2007 and reviewed in 2010
Top Guideline No. 37a. RCOG. April 2015 3. Abdul Sultan A, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. BMJ 2013;347:f6099 (risk of 1st VTE is 18x higher in hospitalized v. non-hospitalized pregnant women) 4 According to the 2018 European guidelines, the incidence of AF during pregnancy is 27/100,000 . AF in Western countries. AF is unusual during pregnancy in Western countries and, if it occurs, it is either a benign, lone AF or a haemodynamically significant AF, with or without structural heart disease 
Information for pregnant women or women who have given birth who are receiving low molecular weight heparin. Heparin is an anticoagulant drug. This means that is slows down blood clotting or thins the blood. There are various types of heparin - the type we usually use is a Low Molecular Weight Heparin (LMWH) such as Enoxaparin (also. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion. Information in this statewide guideline is current at the time of publication If > 100kg use higher doses as per secondary care guidelines (not included) LMWH Prophylactic doses as per BNF Dalteparin 2500 units or 5000 units sc OD Enoxaparin 20mg or 40mg sc OD Tinzparin 3500units or 4500 units sc OD . Dose (thromboprophylaxis) in PREGNANCY Heart valve replacement with a mechanical valve requires lifelong anticoagulation. Guidelines currently recommend using a vitamin K antagonist (VKA) such as warfarin. Given the teratogenic effects of VKAs, it is often favorable to switch to heparin-derived therapies in pregnant patients since they do not cross the placenta. However, these therapies are known to be less effective anticoagulants.
For pregnant patients, the ACCP guidelines for dosing of enoxaparin vary. Depending on VTE history, presence of thrombophilia, and use of a mechanical valve, the enoxaparin dose could be 40 mg SC. Multidose vial contains benzyl alcohol, which is associated with gasping syndrome in premature infants. Increased risk of bleeding with doses of 1.5 mg/kg/day or 1 mg/kg q12hr. Dosing considerations. Risk of serious adverse reactions increases in the elderly. Body weight <45 kg may require dose adjustment Round enoxaparin doses to nearest syringe; no upper weight limit a) Check anti-Xalevel 4 hours after 3rddose & contact Hematology for testing approval b) If baseline aPTTelevated: consult Hematology (need anti-Xalevels for dosing) c) See HIT Diagnostic and Treatment Guidelines in Penn Pathways and online formular Treatment of venous thromboembolism in pregnancy. By subcutaneous injection. For Child 12-17 years (body-weight up to 50 kg) 40 mg twice daily, dose based on early pregnancy body-weight. For Child 12-17 years (body-weight 50-69 kg) 60 mg twice daily, dose based on early pregnancy body-weight. For Child 12-17 years (body-weight 70-89 kg
There have been reports of both clinical success7-9 and failure9-12 with enoxaparin in pregnant women. In a retrospective review of 624 pregnancies, Lepercq et al,13 documented a low incidence of maternal adverse effects (bleeding, thrombocytopenia) and no relation of enoxaparin use to the fetal and neonatal adverse effects noted Renal failure (eGFR<30 ml/min/1.73m 2 ) and eclampsia are also indications for haematology advice with thromboprophylaxis in pregnancy. The Trust has historically used other guidelines and simplified enoxaparin complex medication stickies
In one study, 50 women with thrombophilia (including 20 factor V Leiden heterozygotes) and recurrent pregnancy loss were treated with enoxaparin throughout 61 subsequent pregnancies. The live birth rate was 75% with enoxaparin prophylaxis, compared to 20% in prior untreated pregnancies [Brenner et al 2000] pregnancy, after individualized beneﬁt-risk assessment. This systematic review and meta-analysis demonstrate the safety of enoxaparin in pregnancy. Though reports of thromboembolic events, thrombocytopenia, and teratogenicity were rare, enoxaparin use during pregnancy was associated with lower occurrence of pregnancy loss when compared with.
Effect While Trying to Conceive: Enoxaparin is a blood thinner and blood thinners have been use to improve fertility in some cases.There is no proof enoxaparin inhibits fertility in men or women. Effects on Pregnancy: Enoxaparin does not cross the placenta, so there is no known danger to the fetus when taking this blood thinner.There are preparations of the drug that contain benzyl alcohol ¥Enoxaparin is the preferred form of anticoagulation Appendix 4b: Anticoagulation Dosing Guidelines (Pregnant Patients) Dosing weight for PREGNANT patients should be actual body weight and POST-PATRUM dosing should be PRE-PREGNANCY weight *Target anti-Xa levels between 0.3 - 0.7 units/m The manufacturer of Lovenox, Sanofi-Aventis submitted to FDA 170 cases of spinal or epidural hematoma associated with Lovenox thromboprophylaxis and neuraxial anesthesia (spinal or epidural) or. 4. Enoxaparin. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at nccn.org. Accessed November 7, 2018. 5. Cancer-associated venous thromboembolic disease (Version 1.2019). In: National Comprehensive Cancer Network Clinical Practice Guidelines. Available at nccn.org. 6
Lovenox activity, routine monitoring of coagulation parameters is not required [see: Warnings and Precautions (5.9)]. For subcutaneous use, Lovenox should not be mixed with other injections or infusions. For intravenous use (i.e., for treatment of acute STEMI), Lovenox can be mixed with normal saline solution (0.9%) or 5% dextrose in water The EMA has set guidelines for LMWH products such as enoxaparin that only require the products to contain a similar (as opposed to the same) active ingredient to that contained in another already.
Caring for women with mechanical heart valves (MHVs) in pregnancy poses one of the greatest clinical challenges in our specialty. Pregnancy is a prothrombotic state because of the relative increases in fibrinogen, plasminogen activator inhibitors, clotting factors, Von Willebrand factor, and platelet adhesion molecules, and concomitant decreases in protein S activity Enoxaparin is not licensed in pregnancy but is used off-label for the prevention and treatment of venous thrombosis in pregnancy, and in the treatment of the anti-phospholipid syndrome. The use in pregnancy is supported by national and local guidelines (Somerset prescribing forum and drugs and therapeutic committees) Enoxaparin SCG Page 1 of 2 Treatment and prophylaxis of VTE during pregnancy and following delivery. (Guidance of the Royal College of Obstetricians and Gynaecologists Green Top Guideline No 37a www.rcog.org.uk). Essential information such as dose, weight, renal function, indication and duration of treatment should be. . Higher doses (50-100% of therapeutic doses depending on the setting) are indicated in very high. Enoxaparin (Lovenox) 40 mg subcutaneous q 12 hrs, starting 12 hrs post op BMI>50 kg/M2 Enoxaparin (Lovenox) 60 mg subcutaneous q 12 hrs, starting 12 hrs post op B. High Risk (multiple episodes of VTE, or anti-thrombin III deficiency) Individualize care Weight-based dosing is superior to fixed dosing, eg, enoxaparin 0.5 mg/kg every 12 hours II
.75-1mg/kg BID or 1/5mgkg daily) Upon catheter removal, consider withholding enoxaparin for > 4 hours UFH Prophylaxis UFH: No contraindications to timin Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol . 1999 Nov. 181(5.
Last updated July 1, 2021 at 11:53 a.m. EST. Available data suggest that symptomatic pregnant and recently pregnant women with COVID-19 are at increased risk of more severe illness compared with nonpregnant peers (Ellington MMWR 2020, Collin 2020, Delahoy MMWR 2020, Khan 2021).Currently, there are insufficient data in pregnant health care personnel that stratify risk by either gestational age. A 2007 study with a total inclusion of > 144 000 patients reported a lower incidence of VTE with fondaparinux (1.5%) compared with enoxaparin (2.3%), dalteparin (2.1%) and UFH (4.2%). 56 Also, the latest ACCP guidelines recommend fondaparinux as a method of VTE prophylaxis for patients undergoing THR, TKR or hip fracture surgery. 31 However. The COVID-19 Treatment Guidelines Panel (the Panel) recommends that potentially effective treatment for COVID-19 should not be withheld from pregnant women because of theoretical concerns related to the safety of therapeutic agents in pregnancy (AIII) . Decisions regarding the use of drugs approved for other indications or investigational drugs.
enoxaparin Anti-Xa level drawn within 2.5-5.5 hours after at least 3 consecutive identical doses of enoxaparin; with no more than one syringe of a different dose given prior to the consecutive identical doses Patients receiving enoxaparin for VTE prophylaxis Pregnant Patients 1Rodvold KA, Erdman SM, Sprandel KA, Cipolle RJ, Pollak ES. Heparin. Department of Health: Anticoagulation and prophylaxis using LMWH in adult inpatients . 4. Guideline 4.1 Indications The low molecular weight heparins (LMWH), dalteparin and enoxaparin, are approved for use i a. Heparin 5000 units Q 8 hrs and SCDs may be substituted for enoxaparin during the indwelling time. Renal Impairment H. For patients with a significant rise in SrCr (> 50%) or a creatinine clearance < 30 mL/min, enoxaparin may be renally adjusted to 30 mg daily or subcutaneous heparin 5000 units Q 8 hrs may substituted for enoxaparin. a
Enoxaparin does not affect PTT or INR . Anti-factor Xa. Levels can be measured and are generally used to monitor enoxaparin activity in certain subgroups of patients. Anti-Xa levels may be recommended in underweight, obese, pregnant, or renally impaired patients. Anti-Xa levels should be checked at their peak at 4 hours after dosing (both q12. 2.5 bid, rivaroxaban 10 mg daily or Enoxaparin SQ daily (prevention dose adjusted for weight). • There is substantial controversy about the use of escalated doses of anticoagulants to prevent thrombotic events in COVID-19 so no recommendations are offered. • Critical illness with COVID-19 adds complexity to the use of oral anticoagulant
Pregnant . Unable to obtain BLE duplex . Morbidly obese LMWH Group: Enoxaparin 30mg q12h -First dose within 24 hours of admit . Exceptions: -Withheld 12 hours before any surgery . IPC Group: -Sleeve disuse was tolerated for up to 8 hours consecutively -longer intervals resulted in exclusion from the analysi For pregnant or postpartum women who are admitted to hospital (for any indication) and who have COVID-19, use prophylactic doses of anticoagulants, preferably low-molecular weight heparin (LMWH: eg, enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk for major bleeding or imminent birth pregnancy, including after cesarean delivery. This Consult discusses the different guidelines on prophylaxis of venous thromboembolism after cesarean delivery and provides recommendations based on the available evidence. The recommendations by the Society for Maternal-Fetal Medicine are as follows observed peak anti-Xa levels for 1.5mg/kg q24h dosing of LMWHs (e.g enoxaparin 1.5mg/kg q24h) = 1-2 units/mL. if measured, check trough anti-Xa level at end of dosing interval (just before next dose) expected trough anti-Xa levels = < 0.5 units/mL. higher troughs suggest impaired clearance - an increased dosing interval may be indicated
The 2015 RCOG guidelines state that prophylaxis should be used from the start of pregnancy in women with four VTE risk factors, from week 28 in those with three risk factors, and women with two risk factors should receive 10 days of post-partum prophylaxis .This implies that nearly half of pregnant women are eligible for post-partum prophylaxis  The use of enoxaparin for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied. In a clinical study of pregnant women with mechanical prosthetic heart valves given Clexane (1 mg/kg twice daily) to reduce the risk of thromboembolism, 2 of 8 women developed clots resulting in blockage of the. Enoxaparin should be administered subcutaneously. The recommended dose of enoxaparin for the treatment of pulmonary embolism in uncomplicated cases with low risk of recurrence is 1.5 mg per kg every 24 hours until adequate oral anticoagulation is established [BNF 76, 2018]. Enoxaparin is contraindicated in [ABPI, 2018a; BNF 76, 2018] The guidelines have consistently recommended an INR of <1.5 before removal of epidural catheter, although it has been questioned. A series of 11,235 patients received epidural analgesia for total knee replacement in which they were given 5-10 mg of warfarin the night before surgery Just found out I am pregnant (yeah!!), so only 4 weeks along. I have MTHFR and had a DVT and PE in 1998. During my 1st pregnancy I took Lovenox starting in week 12 until a few days before my scheduled induction because as others have said you can not be on Lovenox and get the epidural
6.2.3 If an anti-Xa level is deemed necessary, it should be drawn 4-6 hours after enoxaparin administration with an anti-Xa goal of 0.1-0.3 units/mL. 16. Disclaimer Clinical practice guidelines assist clinicians by providing a framework for the evaluation and treatment of patients. This guideline outlines the preferred approach for most patients Dalteparin Enoxaparin Prophylaxis 2500-5000 units daily 20-40mg daily DVT treatment 100 Units/kg BD 1mg/kg BD or 1.5mg/kg daily Monitoring of the anti-Xa level is not required except in the following circumstances: pregnancy (note: once daily administration for therapeutic anticoagulation is not recommended in pregnancy Based on CrCl, dose reduction was warranted for 15 patients. Four (including one of the four obese patients) received 20 mg enoxaparin daily, as per guidelines for non-obese patients; the remaining 11 received the standard 40-mg daily dose. 2 Nearly all normal weight patients (127/141) received an appropriate dose according to their renal function failure) contraindications, weight and patient preference (see anticoagulation guideline) Prophylactic dose in patient with CrCl≥30ml/min Weight (kg) Daily Dose <50 Enoxaparin(Inhixa®) 20mg daily 50-100 Enoxaparin(Inhixa®) 40mg daily 101-150 Enoxaparin(Inhixa®) 40mg twice daily >150 Enoxaparin(Inhixa®) 60mg twice dail weight-based high-dose enoxaparin regimen resulted in a target anti-Xa level of0.2-0.5 IU/ml in 85% of patients. This is in comparison to 82% of patients in the standard dose group and 36% in the weight-based low-dose group. Bickford et al. evaluated a weight-based enoxaparin regimen and found a dose of 0. CrCl >30: Enoxaparin 40 mg SQ Q12H CrCl ≤30: Enoxaparin 40 mg SQ daily; Alternative - heparin 7,500 units SQ Q8hrs o If anticoagulant prophylaxis is contraindicated, apply sequential compression device (SCD) per standard MSHS VTE prophylaxis protocol. SCD should not be placed if a DVT i